Press release
Acute Radiation Syndrome Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Bolder BioTechnology, Neumedicines, Humanetics, Statera, Chrysalis, Pluristem, Meabco, iNtRON Biotechnology
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 8+ pipeline drugs in the Acute Radiation Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years."Acute Radiation Syndrome Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Acute Radiation Syndrome Therapeutics Market.
The report provides a detailed description of the Acute Radiation Syndrome drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Acute Radiation Syndrome Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/acute-radiation-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Acute Radiation Syndrome Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Acute Radiation Syndrome therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Radiation Syndrome treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Acute Radiation Syndrome drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Acute Radiation Syndrome treatment market.
Learn More about the Clinical and Commercial Development Activities in the Acute Radiation Syndrome Therapeutics Domain:
https://www.delveinsight.com/report-store/acute-radiation-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Acute Radiation Syndrome Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Acute Radiation Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Request for Sample PDF to Understand More About the Acute Radiation Syndrome Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/acute-radiation-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Acute Radiation Syndrome Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Acute Radiation Syndrome. Currently, Statera BioPharma is leading the therapeutics with its Acute Radiation Syndrome drug candidates in the most advanced stage of clinical development.
Acute Radiation Syndrome Companies in the Therapeutics Market Include:
• Bolder BioTechnology
• Neumedicines
• Humanetics Corporation
• Statera BioPharma
• Chrysalis BioTherapeutics
• Pluristem Therapeutics
• Meabco
• iNtRON Biotechnology
And Many Others
Emerging and Marketed Acute Radiation Syndrome Therapies Covered in the Report Include:
• STAT-600: Statera BioPharma
• PLX-R18: Pluristem Therapeutics
And Many More
Get an in-depth Assessment of the Emerging Therapies and Acute Radiation Syndrome Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/acute-radiation-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Acute Radiation Syndrome Current Treatment Patterns
4. Acute Radiation Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Acute Radiation Syndrome Late-Stage Products (Phase-III)
7. Acute Radiation Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Radiation Syndrome Discontinued Products
13. Acute Radiation Syndrome Product Profiles
14. Acute Radiation Syndrome Companies
15. Acute Radiation Syndrome Drugs
16. Dormant and Discontinued Products
17. Acute Radiation Syndrome Unmet Needs
18. Acute Radiation Syndrome Future Perspectives
19. Acute Radiation Syndrome Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/acute-radiation-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Messenger RNA (mRNA)-based Vaccines and Therapeutics Market
https://www.delveinsight.com/report-store/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market
Narcolepsy Market
https://www.delveinsight.com/report-store/narcolepsy-market
Osteoporosis Market
https://www.delveinsight.com/report-store/osteoporosis-market
Carcinoid Tumor Syndrome Market
https://www.delveinsight.com/report-store/carcinoid-tumor-syndrome-market
Migraine Market
https://www.delveinsight.com/report-store/migraine-market
Emphysema Market
https://www.delveinsight.com/report-store/emphysema-market
Substance use disorder Market
https://www.delveinsight.com/report-store/substance-use-disorder-market
Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market
Campylobacter Infections Market
https://www.delveinsight.com/report-store/campylobacter-infections-market
mRNA Vaccine and Therapeutics Market
https://www.delveinsight.com/report-store/mrna-vaccine-and-therapeutics-market
Breast Pumps Market
https://www.delveinsight.com/report-store/breast-pumps-market
Negative Pressure Wound Therapy Systems Market
https://www.delveinsight.com/report-store/negative-pressure-wound-therapy-systems-market
Obsessive-Compulsive Disorder Market
https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market
Diabetic Eye Disease Market
https://www.delveinsight.com/report-store/diabetic-eye-disease-market
Seborrhoeic Dermatitis Market
https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
Hernia Repair Devices Market
https://www.delveinsight.com/report-store/hernia-repair-devices-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute Radiation Syndrome Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Bolder BioTechnology, Neumedicines, Humanetics, Statera, Chrysalis, Pluristem, Meabco, iNtRON Biotechnology here
News-ID: 3129540 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Syndrome
"Understanding Rett Syndrome: Trends and Advances in the Rett Syndrome Market"
The Rett Syndrome Market, valued at USD 225.02 million in 2022, is anticipated to surge to USD 515.06 million by 2029, reflecting a significant Compound Annual Growth Rate (CAGR) of 10.23% from 2023 to 2029.
Overview of the Rett Syndrome Market:
Rett syndrome, a rare genetic neurological and developmental disorder primarily impacting females, hinders brain development and causes progressive loss of motor skills and language. The market report underscores technological advancements…
MISME Syndrome Market - Navigating Challenges, Embracing Abilities: MISME Syndro …
Newark, New Castle, USA: The "MISME Syndrome Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
MISME Syndrome Market: https://www.growthplusreports.com/report/misme-syndrome-market/8883
This latest report researches the industry structure, sales, revenue,…
Felty Syndrome Market - A Dedicated Approach to Felty Syndrome Care and Empowerm …
Newark, New Castle, USA: The "Felty Syndrome Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Felty Syndrome Market: https://www.growthplusreports.com/report/felty-syndrome-market/8440
This latest report researches the industry structure, sales, revenue,…
MISME Syndrome Market - Transforming Lives: Empowering Recovery from MISME Syndr …
Newark, New Castle, USA - new report, titled MISME Syndrome Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the MISME Syndrome market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global MISME Syndrome market. The report offers an overview of the market, which…
Hepatorenal Syndrome Market - Reimagining Wellness, Redefining Survival: Hepator …
Newark, New Castle, USA - new report, titled Hepatorenal Syndrome Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Hepatorenal Syndrome market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Hepatorenal Syndrome market. The report offers an overview of the market, which…
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syn …
Global Markets Directs, Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2016, provides an overview of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and…
